AOD-9604 in Eyal — Fat Loss Peptide Research Guide
AOD-9604 research guide for Eyal. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
AOD-9604 isn't found on pharmacy shelves in Eyal or virtually any local market — this is a specialist compound distributed through a dedicated online market. The upside of this online-only market is that serious vendors are judged entirely by their analytical documentation, giving researchers more rigorous quality data than local retail ever could. The core quality markers for AOD-9604 are HPLC purity ≥98%, molecular identity confirmed by mass spectrometry, and a bacterial endotoxin panel — all documented in a lot-traced Certificate of Analysis. Use this guide to evaluate AOD-9604 vendors rigorously — the standards covered in this guide apply whether you are in Eyal or anywhere else.
Understanding AOD-9604 — Biology & Evidence
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Eyal comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
AOD-9604 Purchasing Guide
The first step for any Eyal researcher sourcing AOD-9604 is identifying 2-3 vendors with documented positive community reputations — commercial rankings reflect SEO budgets rather than product quality. Mass spectrometry in the COA establishes that the main HPLC peak is actually AOD-9604 and not a structurally similar impurity — HPLC purity alone cannot verify molecular identity. Signs of a credible vendor beyond COA quality: documented vendor history spanning multiple years, customer service that can discuss analytical methods, and cold chain packaging that protects product integrity. Keep lyophilised AOD-9604 at minus 20 degrees Celsius until ready to use; reconstitute only the amount needed for the near-term protocol and keep the remainder frozen.
Order AOD-9604 — ships to Eyal
COA-verified · International tracking · Research grade
AOD-9604 operates outside approved pharmaceutical regulation — researchers should understand that the safety data available for AOD-9604 is based on research literature rather than clinical trials. Proper handling of AOD-9604 requires careful sterile procedure — alcohol-swabbed septum, fresh needles, clean working environment — and consistent cold chain handling. Bacterial endotoxin contamination is the primary safety concern unique to this class of compound — verify endotoxin testing is present in the lot-matched certificate before any injectable research application. The research literature on AOD-9604 should be studied thoroughly before planning any study — study methodologies, dosing, and endpoints vary significantly and conclusions do not uniformly extrapolate.
Frequently Asked Questions
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
